Skip to main content
TipRanks
Go Ultimate75% OFF

Caribou Biosciences (CRBU) Stock Price & Analysis

1,002 Followers

CRBU Stock Chart & Stats

$0.35-$0.01(-2.49%)
At close: 4:00 PM EST
$0.5$1$1.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.35 - $0.36
52-Week Range
$0.35 - $2.49
Previous Close
$0.36
Volume
N/A
Average Volume (3M)
4.63M
Market Cap
$39.10M
Enterprise Value
$68.11M
Total Cash (Recent Filing)
$94.80M
Total Debt (Recent Filing)
$26.34M
Price to Earnings (P/E)
―
Beta
1.92
Next Earnings
Mar 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margin

The approximately 92% TTM gross margin indicates favorable economics at the gross-profit level and substantial value capture from current revenue. If maintained, this provides a foundation for operating leverage as programs advance, although the benefit is currently overwhelmed by substantial operating expenses.

Genome-Editing Platform

The CRISPR-based platform and focus on allogeneic, off-the-shelf immune cells provide a differentiated technology foundation within oncology cell therapy. A reusable editing platform can support multiple candidates and potentially broaden future development opportunities beyond a single product.

Manageable Leverage

Debt-to-equity of approximately 0.34 indicates that leverage is not currently excessive relative to the company’s capital base. This offers some financial flexibility compared with a highly debt-funded structure, even though ongoing losses and declining equity remain important constraints on that flexibility.

Bears Say

Severe Operating Losses

The scale of operating losses relative to revenue shows that CRBU has not yet established a self-sustaining commercial model. Continued high operating expenses can consume capital faster than the business builds revenue, making future progress dependent on successful pipeline execution and additional financing capacity.

Persistent Cash Burn

Operating and free cash flow of approximately negative $93 million demonstrate that the company remains materially dependent on its cash reserves or external capital. Although burn improved from prior periods, the still-negative result limits funding flexibility and leaves less capacity to absorb setbacks or support broad development activity.

Program Retrenchment

Discontinuing two key allogeneic CAR-T programs and reducing the workforce materially narrows the active pipeline and signals a major strategic retrenchment. The associated trial wind-downs, contract changes, and restructuring charges may reduce near-term operating capacity while management evaluates strategic alternatives.

Caribou Biosciences News

CRBU FAQ

What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.35 and its highest was $2.49 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $39.10M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 114 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Nov 05, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.012.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.10.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 108,036,730 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 8.738%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Hedge funds hold Caribou Biosciences shares: the largest hedge-fund position in Caribou Biosciences is 72,324,635 shares, and hedge funds increased their holdings by 5.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology